Combination Oncology - Pt.1 The Importance of Incremental Health Gain on Pricing : IC Fireside Chats - Episode 12
Combination therapies in oncology are changing the game, but the challenge is real: how do you price a drug that only adds incremental benefit when used with another?
In this episode, we explore how payers assess these add-ons and why clinical benefit must be separated from commercial strategy. Omar and Adam walk through real-world examples and ask: What kind of evidence is persuasive when your therapy isn’t the main event, but still adds value?
Topics covered:
How frameworks struggle with incremental benefit
Why oncology poses specific IC challenges
What happens when combination therapies hit misaligned HTA processes
Disclaimer: This presentation is for educational and informational purposes only, and is not intended as legal or policy advice. This presentation is based on non-confidential intelligence. Views expressed by the speakers are personal opinions and should not be attributed to anyone else. No part of this presentation may be reproduced for commercial purposes without the express permission of Verpora.
Never miss an episode
Receive a single email each week with a direct link to the latest IC Fireside Chat— no spam, just the latest episode, straight to your inbox.
Watch Next
